Versant Ventures acquires US $5M Repare Therapeutics IPOs

CPE News (6/23/2020) – Versant Ventures, the largest shareholder of Repare Therapeutics Inc. (NASDAQ: RPTX), disclosed that it has acquired additional 250,000 common shares of Repare Therapeutics for US $5 million, as part of Repare’s initial public offering (IPO).

Repare Therapeutics Inc. completed its proposed IPO on June 23, 2020, issuing 12,650,000 common shares at US $20 per share for gross proceeds of US $253 million.

With the acquisition of shares, Versant indirectly controls 7,237,679 common shares of Repare, representing approximately 19.69% of the outstanding common shares.

Versant Ventures is Repare’s largest shareholder. Other major shareholders included MPM Capital, OrbiMed, Cowen Healthcare, Fonds de solidarité FTQ, and Redmile Group.

Repare’s stock commenced trading on the Nasdaq Global Select Market on June 19, 2020 and closed at US $32.95 on June 23, 2020.

photo credit: Repare Therapeutics

News Release

VERSANT VENTURES FILES EARLY WARNING REPORT IN RESPECT OF REPARE THERAPEUTICS INC.

FOR IMMEDIATE RELEASE

VANCOUVER, British Columbia & MONTREAL, Quebec – JUNE 23, 2020 – Versant Ventures today announced the filing of an early warning report with respect to the ownership of securities in Repare Therapeutics Inc. (the “Company”) by Versant Venture Capital VI, L.P., Versant Vantage I, L.P., Versant Venture Capital V, L.P., Versant Venture Capital V (Canada) LP, Versant Ophthalmic Affiliates Fund I, L.P. and Versant Affiliates Fund V, L.P. (collectively, the “Versant Funds”).

On June 23, 2020, Versant Venture Capital VI, L.P. and Versant Vantage I, L.P. acquired an aggregate of 250,000 Common Shares of the Company (the “Common Shares”) in the Company’s initial public offering of 12,650,000 Common Shares. The 250,000 Common Shares are referred to as the “Acquired Shares”.

Immediately prior to the acquisition of the Acquired Shares, the Versant Funds had beneficial ownership of, and control or direction over, 6,987,679 Common Shares of the Company, representing approximately 29.92% of the outstanding Common Shares. The 250,000 Acquired Shares represent approximately 0.68% of the outstanding Common Shares.
Immediately following the acquisition of the Acquired Shares, the Versant Funds have beneficial ownership of, and control or direction over, 7,237,679 Common Shares of the Company, representing approximately 19.69% of the outstanding Common Shares.

The Acquired Shares were issued by the Company at a price of US$20.00 per Common Share (or approximately C$27.03), representing an aggregate price of US$5,000,000.00 (or approximately C$6,757,500.00). The Acquired Shares were acquired for investment purposes, and in the future, the Versant Funds may discuss with management and/or the board of directors of the Company business transactions and other opportunities and may further purchase, hold, vote, trade, dispose or otherwise deal in the securities of the Company, in such manner as they deem advisable, depending on market and other conditions.

An early warning report will be filed by the Versant Funds in accordance with applicable securities laws and will be available on SEDAR under the Company’s profile at www.sedar.com or may be obtained directly from the Versant Funds upon request at the telephone number below. The Company’s head and registered office is located at 7210 Frederick-Banting, Suite 100, Montréal, Québec H4S 2A1. The address of each of the Versant Funds is One Sansome Street, Suite 3630, San Francisco, CA 94104.

Contact Information:
Steve Edelson, senior director of communications and investor relations
415-801-8088
sedelson@versantventures.com